30 closest matches · ranked by relevance
Melanoma
Primary: Percentage of Participants With Relapse Free Survival — 28.6 percentage of participants
Unresectable Malignant Neoplasm · Melanoma · Metastatic Melanoma
Primary: Resectability Rate — 8; 2 Participants
Melanoma
Primary: the Incidence of Highgrade (CTCAE v4.0 Grade 3 or Higher), Treatment Related,Select Adverse Events. — 16; 0; 30; 0 Number of Participants
Melanoma
Primary: Th1/Th2 Normalized Gene Expression — 1.029; 0.119; 0.074; 0.192 fold change
Clinical Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage III Cutaneous Melanoma AJCC v8 · Pathologic Stage IIIA Cutaneous Melanoma AJCC v8
Primary: Pathologic Complete Response Rate (pCR) — 66.7; 13.3; 38.2 percentage of participants
Melanoma
Primary: Recurrence-free Survival (RFS) - All Randomized Participants — NA; NA Months
Melanoma
Primary: Disease-Free Survival (DFS) as Assessed Using Contrast-Enhanced Magnetic Resonance Imaging (MRI) or Contrast Enhanced Computed Tomography (CT) — NA; 36.9; 23.1; 15.4…
Melanoma
Primary: Change From Baseline in Mean Number of Adverse Events (Serious and Non Serious Events) — 13.40; 18.40; 23.80; 19.60 Number of adverse events
Melanoma · Skin Cancer · Cancer
Primary: Overall Objective Response (Complete Response or Partial Response) — 2; 2; 15 participants
Intraocular Melanoma · Melanoma (Skin)
Primary: Percentage of Participants With Immune-related Adverse Events (irAEs) — 80.0; 72.0; 65.4 Percentage of participants
Melanoma · Malignant Melanoma · Stage IIIA Melanoma
Primary: Overall Response Rate, Defined as the Percentage of Patients With a Confirmed Clinical Response (CR) or Partial Response (PR) — 3 Participants
Stage IIIC Cutaneous Melanoma AJCC v7 · Stage IV Cutaneous Melanoma AJCC v6 and v7 · Unresectable Melanoma
Primary: Overall Survival (OS) — 20.4; 20.1 months — p=0.383
Recurrent Melanoma
Primary: Sentinel Lymph Nodes (SLN) Mapping — 25; 25; 25; 4 Sentinel lymph nodes
Stage III Melanoma · Stage IV Melanoma · Unresectable Melanoma
Primary: Change in Kinase Expression — -20.87259; -19.64376; -16.41738; -12.5401 Sum Log 2 Fold Change Kinase Expression
Metastatic Melanoma
Primary: Objective Response Rate (ORR) — 1; 1 Participants
Recurrent Melanoma · Stage IA Skin Melanoma · Stage IB Skin Melanoma
Primary: Percentage of Participants With Successful Intravital Microscopy on Accessible Human Melanoma Tumors During Standard Local Excision — 70 percentage of participants
Recurrent Melanoma
Primary: 2-year Local Recurrence Rate (LRR)/Incidence of Local Recurrence — 10 percentage of patients with LR
Recurrent Melanoma · Stage III Skin Melanoma · Stage IV Skin Melanoma
Primary: Anti-tumor Response Defined as Either a CR, PR, or SD as Defined by RECIST — 1; 8; 6 participants
Cutaneous Melanoma · Mucosal Melanoma · Ocular Melanoma
Primary: Arm C: Number of Participants With the Pathologic Response Rate — 0; 0; 34 Participants
Advanced Melanoma · Unresectable Melanoma
Primary: Overall Response Rate (ORR) — 10 percentage of patients
Malignant Melanoma
Primary: Percentage of Participants With Immune-related Progression-Free Survival (irPFS) at 6 Months — 38.6 percentage of participants
Metastatic or Unresectable Cutaneous Melanoma
Primary: Progression-Free Survival (PFS) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 — 2.83; 1.51 Months — p=< 0.001
Melanoma Stage Iii · Melanoma Stage Iv · Melanoma
Primary: The Antitumor Effect of Denosumab Alone as Represented by the Change in Recent Thymic Emigrant Cells in Peripheral Blood — 2.69; 2.42; 2.55; 1.92 number of cell per…
Melanoma
Primary: Number of Subjects With Best Overall Tumor Response — 1; 1; 12; 4 Participants
Metastatic Melanoma
Primary: Complete Response — 7; 3 Participants
Acral Lentiginous Malignant Melanoma · Recurrent Melanoma · Stage IIIA Melanoma
Primary: Objective Response Rate — 1; 3; 14; 7 participants
Melanoma · Lymph Node Cancer
Primary: Major Pathologic Response Rate (MPR) — 14; 3; 3; 10 Participants
Malignant Melanoma
Primary: Percentage of Participants Experiencing Any Grade 3 or 4 Adverse Events (AEs) as Determined by National Cancer Institute-Common Toxicity Criteria for Adverse Events…
Melanoma · Malignant Melanoma · Melanoma, Experimental
Primary: Clinical Response — 1; 3; 3; 2 Participants
Non-small Cell Lung Cancer
Primary: Progression Free Survival (PFS) at 18-month — 65.5; 66.3 Percentage of participants